Acneiform rash during lung cancer therapy with erlotinib (Tarceva®)
作者： Agnieszka Owczarczyk-Saczonek , Henryk Witmanowski , Waldemar Placek
关键词: Acneiform rash 、 Side effect 、 Egfr inhibition 、 Tyrosine kinase 、 Lung cancer 、 Epidermal growth factor receptor 、 Medicine 、 Erlotinib 、 Cancer research 、 Incidence (epidemiology) 、 Pharmacology 、 Immunology and Allergy 、 Dermatology
摘要: Tyrosine kinase inhibitors are currently applied in the treatment of non-small cell lung cancer with overexpressed epidermal growth factor receptor (EGFR). Acneiform rash is earliest and most characteristic side effect EGFR inhibition. The incidence may be as high 50-100% cases. We report a case 47-year-old patient who devel oped acneiform after 1.5 weeks erlotinib.
sci-hub.se 参考文章(11)
L M Ehmann, T Ruzicka, A Wollenberg, Cutaneous side-effects of EGFR inhibitors and their management. Skin therapy letter. ,vol. 16, pp. 1- 3 ,(2011)
Ulrich Rodeck, Monika Jost, Csaba Kari, The EGF receptor - an essential regulator of multiple epidermal functions. European Journal of Dermatology. ,vol. 10, pp. 505- 510 ,(2000)
Roman Perez-Soler, Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer Clinical Cancer Research. ,vol. 13, pp. 4589- ,(2007) , 10.1158/1078-0432.CCR-07-0541
Muhammad Wasif Saif, Irene Merikas, Sotirios Tsimboukis, Kostas Syrigos, None, Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. Journal of the Pancreas. ,vol. 9, pp. 267- ,(2008)
Bret Wacker, Tina Nagrani, Jacqueline Weinberg, Karsten Witt, Gary Clark, Pablo J. Cagnoni, Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies Clinical Cancer Research. ,vol. 13, pp. 3913- 3921 ,(2007) , 10.1158/1078-0432.CCR-06-2610
L. Castillo, M.C. Etienne-Grimaldi, J.L. Fischel, P. Formento, N. Magné, G. Milano, Pharmacological background of EGFR targeting Annals of Oncology. ,vol. 15, pp. 1007- 1012 ,(2004) , 10.1093/ANNONC/MDH257
K. Potthoff, R. Hofheinz, J.C. Hassel, M. Volkenandt, F. Lordick, J.T. Hartmann, M. Karthaus, H. Riess, H.P. Lipp, A. Hauschild, T. Trarbach, A. Wollenberg, Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion Annals of Oncology. ,vol. 22, pp. 524- 535 ,(2011) , 10.1093/ANNONC/MDQ387
Román Pérez‐Soler, Jean Pierre Delord, Allan Halpern, Karen Kelly, James Krueger, Bartomeu Massutí Sureda, Joachim von Pawel, Jennifer Temel, Salvatore Siena, Denis Soulières, Leonard Saltz, James Leyden, HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum Oncologist. ,vol. 10, pp. 345- 356 ,(2005) , 10.1634/THEONCOLOGIST.10-5-345
W. Jacot, D. Bessis, E. Jorda, M. Ychou, M. Fabbro, J-L. Pujol, B. Guillot, Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours British Journal of Dermatology. ,vol. 151, pp. 238- 241 ,(2004) , 10.1111/J.1365-2133.2004.06026.X
S. Segaert, E. Van Cutsem, Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Annals of Oncology. ,vol. 16, pp. 1425- 1433 ,(2005) , 10.1093/ANNONC/MDI279